Retatrutide vs Tirzepatide: Triple Agonist Against Dual, and What the Evidence Supports

In SURMOUNT-1, a phase 3 trial, tirzepatide produced roughly 21% mean body-weight reduction at 72 weeks at the highest dose. In its phase 2 obesity trial, retatrutide produced roughly 24% at 48 weeks in the 12 mg group. Those two figures are quoted side by side constantly, and the comparison is weaker than it looks.

Phase 2 trials are smaller, shorter, and select their participants more narrowly than phase 3. Effect sizes very often shrink when a compound moves from phase 2 into a larger, longer, more heterogeneous phase 3 population — that attenuation is one of the most reliable patterns in clinical development. A 24% phase 2 result and a 21% phase 3 result are not two points on the same scale.

The honest summary is that retatrutide looks more potent and has not yet been tested to the standard tirzepatide has already met.

Tirzepatide holds an EMA marketing authorisation in the European Union as Mounjaro, which means a published EPAR, an approved label, defined indications and a formal safety profile. Retatrutide has none of that. It sits in Eli Lilly's clinical pipeline and has not been authorised by the EMA for any indication.

This is the difference that matters most in practice and is the one most often skipped. An authorised medicine has a known adverse-event profile assembled from thousands of monitored patients. An investigational compound has a phase 2 safety signal and open questions that only larger trials answer.

Both are peptide analogues delivered subcutaneously, both are supplied lyophilised for research use and require reconstitution, and both share the gastrointestinal adverse-event pattern that characterises the incretin class — nausea, diarrhoea and constipation, most pronounced during dose escalation.

Handling is identical in kind: store lyophilised material cold, reconstitute with bacteriostatic water, keep the reconstituted vial refrigerated and respect the working window. Neither tolerates repeated freeze-thaw cycles.